研究者情報
検索ページ

（最終更新日：2024-04-10 11:26:32）   ミズカミ　タクロウ   MIZUKAMI TAKURO   水上拓郎    所属   医学部医学科 臨床腫瘍学    職種   非常勤講師

■ 学術雑誌 1. 原著　 Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild-type metastatic colorectal cancer: A phase II trial (HYBRID) 2024/04 2. 原著　 Chemotherapy after nivolumab for advanced gastric cancer (REVIVE): a prospective observational study 2023/11 3. 原著　 Clinical utility of geriatric assessment tools in older patients with gastrointestinal cancer. 2023/05 4. 原著　 Genomic Landscape of Primary Tumor Site and Clinical Outcome for Patients with Metastatic Colorectal Cancer Receiving Standard-of-Care Chemotherapy. 2022/05 5. 原著　 The molecular landscape of pancreatobiliary cancers for novel targeted therapies from real-world genomic profiling. 2022/05 6. 原著　 Clinical Utility of Genomic Profiling Tests in Patients with Advanced Gastrointestinal Cancers 2022/03 7. 原著　 Impact of Body Weight Loss on Survival in Patients with Advanced Gastric Cancer Receiving Second-Line Treatment 2022/03 8. 原著　 Prediction of esophagogastric varices associated with oxaliplatin administration 2021/11 9. その他　 Role of nutritional care and general guidance for patients with advanced or metastatic gastric cancer 2021/08 10. 原著　 An observational study on nutrition status in gastric cancer patients receiving ramucirumab plus taxane: BALAST study 2021/04 11. 原著　 Impact of Body Weight Loss on Survival in Patients with Advanced Gastric Cancer Receiving Second-Line Treatment 2021/03 12. 原著　 Clinical practice guidelines for the management of liver metastases from extrahepatic primary cancers 2021 2020/11 13. 症例報告　 Inferior mesenteric arteriovenous fistula during treatment with bevacizumab in colorectal cancer patient: A case report 2020/11 14. 原著　 Prospective evaluation and refinement of an S-1 dosage formula based on renal function for the clinical application 2020/11 15. その他　 REVIVE study: a prospective observational study in chemotherapy after nivolumab therapy for advanced gastric cancer. 2020/09 16. 総説・解説　 胃がん一次治療HER2以外の分子標的薬の開発 2020/05 17. 原著　 Phase I study of the anti-heparin-binding epidermal growth factor-like growth factor antibody U3-1565 with cetuximab in patients with cetuximab- or panitumumab-resistant metastatic colorectal cancer 2020/04 18. 総説・解説　 消化器がんの病態と治療 2020/04 19. 総説・解説　 消化器障害 2019/10 20. 原著　 Analysis of fistula formation of T4 esophageal cancer patients treated by chemoradiotherapy. 2019/09 21. 原著　 Clinical Implications of Decreased Computed Tomography Value after Ramucirumab in Advanced Gastric Cancer 2019/06 22. 総説・解説　 Targeting EGFR and RAS/RAF Signaling in the Treatment of Metastatic Colorectal Cancer: From Current Treatment Strategies to Future Perspectives. 2019/04 23. 原著　 A randomized phase II study of nutritional and exercise treatment for elderly patients with advanced non-small cell lung or pancreatic cancer: the NEXTAC-TWO study protocol. 2019/03 24. 症例報告　 Esophagogastric varices were diagnosed in a non-cirrhotic liver case during long-term follow-up after oxaliplatin-based chemotherapy 2018/12 25. 総説・解説　 免疫療法 2018/09 26. 総説・解説　 Pan-Asian adapted ESMO consensus guidelineの概要 2018/07 27. 総説・解説　 クリニカルシークエンスを基にした分子標的治療の展開 2018/07 28. 原著　 Chemotherapy in cancer patients undergoing hemodialysis: A nationwide study in Japan 2018/01 29. 原著　 Early morphological change for predicting outcome in metastatic colorectal cancer after regorafenib 2017/12 30. 原著　 がん患者の終末期医療における看取り場所の聴取後の在宅がん緩和医療移行の実態 2017/12 31. 原著　 "Early morphological change for predicting outcome in metastatic colorectal cancer after regorafenib" 2017/11 32. 総説・解説　 Profile of trifluridine/tipiracil hydrochloride in the treatment of metastatic colorectal cancer: efficacy, safety, and place in therapy 2017/09 33. 原著　 Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinib. 2017/06 34. 総説・解説　 多遺伝子アッセイを用いた結腸がん術後再発リスク予測の可能性―SUNRISE試験の結果から 2017/06 35. 原著　 Identification of FGFR3-TACC3 fusion in esophageal cancer 2017/02 36. 原著　 Significance of FGF9 Gene in Resistance to Anti-EGFR Therapies Targeting Colorectal Cancer:A Subset of Colorectal Cancer Patients With FgF9 Upregulation May Be Resistant to Anti-EGFR Therapies 2017/01 37. 原著　 Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study. 2016/07 38. 総説・解説　 消化管がん化学療法2016「2. 切除不能・再発胃がんの新薬・バイオマーカー開発の現状と展望」 2016/07 39. 原著　 Infusion site adverse events in breast cancer patients receiving highly emetic chemotherapy with prophylactic anti-emetic treatment with aprepitant and fosaprepitant: A retrospective comparison. 2016/04 40. 原著　 Significance of FGF9 gene in resistance to anti-EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti-EGFR therapies. 2016/02 41. 原著　 Clinicopathological and genetic differences between low-grade and high-grade colorectal mucinous adenocarcinoma. 2015/12 42. 総説・解説　 Pharmacogenomics and biomarker; FGFR阻害薬のバイオマーカー 2015/09 43. 原著　 EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition. 2015/07 44. 原著　 An activating ALK gene mutation in ALK IHC-positive/FISH-negative nonsmall-cell lung cancer. 2015/05 45. 原著　 Predictability of the anti-tumor efficacy of cetuximab plus irinotecan based on skin rash severity according to observation period in patients with metastatic colorectal cancer after fluorouracil, irinotecan, and oxaliplatin failure 2015/04 46. 原著　 Predictability of the anti-tumor efficacy of cetuximab plus irinotecan based on skin rash severity according to observation period in patients with metastatic colorectal cancer after fluorouracil, irinotecan, and oxaliplatin failure 2015/01 47. 総説・解説　 がん外来化学療法のリアル 2014/07 48. 総説・解説　 最新胃癌学　一次治療、二次治療のレジメン選択 2014/01 49. 総説・解説　 ML18147試験 2013/12 50. 総説・解説　 がん薬物治療専門医のための模擬テスト41-解答と解説- 2013/11 51. 総説・解説　 胃癌の薬物療法　a)切除不能・再発癌 2013/11 52. 総説・解説　 切除不能・再発胃癌に対する分子標的薬の導入 2013/03 53. 総説・解説　 進行大腸がんに対するbevacizumab beyond progressionの評価 2012/10 54. 総説・解説　 食道がん化学療法に用いられるレジメン 2012/10 55. 症例報告　 歯科で診断が困難であった根尖性歯周炎による不明熱の1例 2011/11 5件表示 全件表示(55件)

■ 学会発表 1. 初診時切除不能と判断したがConversion surgery後も長期生存している非乳頭部十二指腸癌の1例 （口頭発表，一般） 2023/02/17 2. 食道癌に対してニボルマブ治療開始13か月後、尿糖自己測定によりirAEによる劇症1型糖尿病を早期に捉えた1例 （口頭発表，一般） 2022/09/10 3. 切除可能大腸がん高齢患者の高齢者機能評価と臨床経過 （ポスター） 2022/06/18 4. Somatostatin receptor: a potential new therapeutic target for primary mucinous neoplasm of the appendix. （口頭発表） 2022/02 5. 食道癌に対してニボルマブ治療中、尿糖自己測定により劇症1 型糖尿病を早期に捉えた1 例 （口頭発表，一般） 2022/01/22 6. Genomic landscape in small intestine cancer from real-world data (RWD) of clinical genomic testing.  2022/01/20 7. Genomic landscape in advanced gastric cancer from real-world data (RWD) of clinical genomic testing （ポスター，一般） 2021/09/21 8. Genomic alterations for novel targeted therapies in pancreatobiliary cancers from real-world data （ポスター，一般） 2021/06/04 9. 免疫チェックポイント阻害薬の免疫関連有害事象に対する治療前の抗体検査の意義. （口頭発表，一般） 2021/05/29 10. 進行胃癌に対するTAS-118とオキサリプラチンを用いた周術期化学療法 （口頭発表，シンポジウム・ワークショップ・パネルディスカッション等） 2021/03/04 11. A phase I/II trial of trifluridine/tipiracil in combination with irinotecan in patients with advanced gastric cancer refractory to fluoropyrimidine, platinum, and taxane.  2021/02/19 12. Anti-VEGF inhibitors and Renal Safety in Onco-Nephrology consortium -Urinary Protein/Creatinine ratio [VERSiON UP study]  2021/02/19 13. 進行固形がん患者における免疫チェックポイント阻害薬導入前の抗体検査と免疫関連有害事象との関連性  2021/02/19 14. A phase I/II trial of trifluridine/tipiracil in combination with irinotecan in patients with advanced gastric cancer refractory to fluoropyrimidine, platinum, and taxane. （ポスター） 2021/01/15 15. A translational study to evaluate genomic markers and concordance with circulating-tumor DNA and circulating tumor cells to predict clinical outcomes in gastrointestinal and pancreatobiliary cancers: Valor trial. （ポスター） 2021/01/15 16. Feasibility study of TAS-118 plus oxaliplation as perioperative chemotherapy for patients with advanced gastric cancer(APOLLO-11). （ポスター，一般） 2021/01/15 17. Anti-VEGF inhibitors and Renal Safety in Onco-Nephrology consortium -Urinary Protein/Creatinine ratio [VERSiON UP study] （ポスター） 2020/11/22 18. Practical situations of the clinical trial using digital scales and devices （口頭発表） 2020/11/10 19. Multi-gene panel testing in patients with gastro-intestinal cancers: A retrospective study. （口頭発表，一般） 2020/10/23 20. 高齢者胃癌に対する治療の工夫 （口頭発表，シンポジウム・ワークショップ・パネルディスカッション等） 2020/10/22 21. A phase I/II trial of trifluridine/tipiracil in combination with irinotecan in patients with advanced gastric cancer refractory to fluoropyrimidine, platinum, and taxane.  2020/01/15 22. Identification of Site-specific Genome Alterations in Metastatic Colorectal Cancer: Sub-study 003 of the SCRUM-Japan GI-SCREEN.  2019/10/26 23. Association of gastric acid suppression with efficacy of immune checkpoint inhibitors (ICIs) in advanced cancer patients （口頭発表） 2019/10/24 24. International clinical practivce guideline for metastatic liver tumor: Chmotherapy （口頭発表） 2019/10/24 25. Biological difference of tumour mutational burden (TMB) and microsatellite instability (MSI) status in patients (pts) with somatic vs germline BRCA1/2-mutated advanced gastrointestinal (GI) cancers using cell-free DNA (cfDNA) sequencing analysis in the GOZILA study （口頭発表） 2019/09/30 26. in advanced solid cancer patients （口頭発表） 2019/09 27. Association of gastric acid suppression with efficacy of immune checkpoint inhibitors （口頭発表） 2019/07/20 28. 胃がん栄養 （ポスター） 2019/03/08 29. Chemotherapy after progREssiVe dIsease of niVolumab thErapy (REVIVE study) （口頭発表） 2019/02/28 30. Chemotherapy after progREssiVe dIsease of niVolumab thErapy(REVIVE study)  2019/02/28 31. Identification of site-specific genome alterations in metastatic colorectal cancer: Sub-study 003 of the SCRUM-Japan GI-SCREEN  2019/01 32. Prospective evaluation of a developed S-1 dosage formula based on renal function.  2019/01 33. REVIVE study: Prospective observational study of efficacy and safety in chemotherapy (CTx) after progREssiVe dIsease of niVolumab (NIV) thErapy for metastatic gastric cancer (mGC).  2019/01 34. Antibiotics may enhance the efficacy of gemcitabine treatment for advanced pancreatic cancer （ポスター） 2018/10/21 35. Dynamic change of immune-related gene expression status during chemoradiotherapy in locally advanced esophageal cancer （ポスター） 2018/10/20 36. The nationwide cancer genome screening project in Japan, SCRUM Japan GISCREEN: Efficient identification of cancer genome alterations in advanced Biliary Tract Cancer. （ポスター） 2018/10/19 37. Regorafenib療法のラーニングカーブ評価 （ポスター） 2018/07/20 38. The Nationwide Cancer Geome Screening Project in Japan, SCRUM-Japan GI-SCREEN: Advanced Colorectal Cancer Cohort  2018/07 39. The Nationwide Cancer Geome Screening Project in Japan, SCRUM-Japan GI-SCREEN: Advanced Pancreatic Cancer Cohort  2018/07 40. Phase I study of the anti-heparin binding-EGF antibody U3-1565 with cetuximab in patients with cetuximab- or panitumumab-resistant metastatic colorectal cancer （ポスター） 2018/04 41. Pharmacokinetics and safety of FOLFOX therapy in patients undergoing hemodialysis  2017/09/08 42. The Nationwide Cancer Genome Screening Project in Japan, SCRUM-Japan GI-SCREEN: Efficient Identification of Cancer Genome Alterations in Advanced Colorectal Cancer.  2017/09/08 43. Clinical Implication of Morphological Changes of Ramucirumab in Metastatic Gastric Cancer  2017/07/27 44. Early morphologic change (EMC) caused by regorafenib (REGO) in patients (pts) with metastatic colorectal cancer (mCRC) （一般） 2017/07 45. Identification of a FGFR3-TACC3 fusion in esophageal cancer  2017/04/01 46. Chemotherapy in cancer patients undergoing hemodialysis: A multicenter study  2016/10/07 47. SCRUM-Japan GI-SCREEN: Efficient Identification of Cancer Genome Alterations in Advanced Colorectal Cancer （口頭発表） 2016/07/28 48. 切除不能進行・再発大腸癌に対するサルベージライン化学療法（regorafenib, TAS102）の後方視的検討 （口頭発表，一般） 2016/07/28 49. 慢性維持透析がん患者におけるがん薬物療法実態調査（J-CANDY試験：多施設共同観察研究）  2016/07/28 50. The Nationwide Cancer Genome Screening Project in Japan, SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced colorectal cancer.  2016/06 51. 聖マリアンナ医科大学病院におけるシスプラチンによる腎障害の実態と軽減対策の効果  2016/03 52. Fibroblast growth factor 9 gene amplification can induce resistance to anti-EGFR therapy in colorectal cancer  2015/09 53. "Fibroblast Growth Factor 9 gene amplification can induce resistance to anti-EGFR therapy in colorectal cancer "  2015/07 54. EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition.  2015/07 55. T4食道癌の瘻孔形成における臨床経過について  2015/07 56. 外来化学療法における発熱性好中球減少症の一症例  2015/07 57. 遠隔転移を有する進行食道扁平上皮癌に対する化学放射線療法の経口摂取改善における臨床的意義  2015/07 58. がん患者の看取る場所についての検討：在宅診療に移行した患者が、病院に再入院する理由を中心に  2014/07/17 59. 電解質異常を伴った高齢在宅患者に発症したVaracyclovir脳症の一例  2011/07/03 60. 不明熱で入院し、歯科で診断に至らなかった根尖性歯周炎の1例  2011/02/05 5件表示 全件表示(60件)